← Back to Clinical Trials
Recruiting NCT06701084

NCT06701084 Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06701084
Status Recruiting
Phase
Sponsor Boston Children's Hospital
Condition Neonatal Epilepsy
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2021-09-02
Primary Completion 2029-11

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Genomic Sequencing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2021-09-02 with a primary completion date of 2029-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families.

Eligibility Criteria

Infant Criteria Inclusion Criteria: * Seizure onset at less than 12 months of age * Enrollment within 6 weeks of seizure-related presentation * Patient at Boston Children's Hospital Exclusion Criteria: * Simple febrile seizures * Acute provoked seizures (e.g., due to sepsis, hemorrhage, electrolyte abnormality, cerebral infarction, hypoxic ischemic encephalopathy, non-accidental injury) * Genetic or acquired cause of epilepsy already identified, including brain magnetic resonance imaging findings consistent with a specific genetic etiology (e.g., tuberous sclerosis complex) * Deceased prior to enrollment Parent Criteria Inclusion Criteria - Parent of eligible infant (see above) Exclusion Criteria \- Not the legal guardian of the eligible infant

Contact & Investigator

Central Contact

Beth R Sheidley, MS

✉ beth.sheidley@childrens.harvard.edu

📞 8572185533

Principal Investigator

Alissa M D'Gama, MD, PhD

PRINCIPAL INVESTIGATOR

Boston Children's Hospital

Frequently Asked Questions

Who can join the NCT06701084 clinical trial?

This trial is open to participants of all sexes, studying Neonatal Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06701084 currently recruiting?

Yes, NCT06701084 is actively recruiting participants. Contact the research team at beth.sheidley@childrens.harvard.edu for enrollment information.

Where is the NCT06701084 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06701084 clinical trial?

NCT06701084 is sponsored by Boston Children's Hospital. The principal investigator is Alissa M D'Gama, MD, PhD at Boston Children's Hospital. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology